Strain-Resolved Therapeutics for the Microbiomes That Run Reproductive Health

The vaginal microbiome alone shapes risk for bacterial vaginosis, urinary tract infections, candidiasis, HPV persistence, sexually transmitted infection acquisition, preterm birth, and IVF success — and the field is now able to engineer it at strain resolution, not just describe it. The Intimate Microbiome Therapeutics & Diagnostics Sub-Institute is built around that capability. It runs strain-level genomic characterization, designs synbiotic formulations, optimizes delivery routes (with explicit recognition that route of administration is as decisive as strain choice), and integrates the major microbiome diagnostic platforms under a single reference standard. It also operates an end-to-end live biotherapeutic product pipeline — discovery through preclinical, Phase 1, Phase 2, Phase 3, and licensure — with synthetic control arms, mandatory human review at every regulatory transition, and tight coordination with the parent Sexual Health Institute and the relevant disease and organ verticals across the platform.

Value proposition:

• Strain-level genomics, formulation, and delivery — not generic probiotic claims
• Diagnostic platforms unified under a single reference standard
• End-to-end live biotherapeutic product pipeline with regulator-grade discipline